PROM1 and glioblastoma: Furthermore, aptamer-based SOMAScan® proteomic assay technology has enabled the identification of 24 serum proteins linked to CD133, which are involved in neuro-oncology signaling pathways, with great potential as clinically valuable predictive biomarkers for diagnostics, treatment monitoring and 1-year survival prediction in GBM [45,46].